A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Clinical trial NCT06577376 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06577376
Sponsor: Shanghai Runshi Pharmaceutical Technology Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Localized Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma Expressing Human Epidermal Growth Factor Receptor-2 (HER-2)Disease Progression After Receiving at Least One and at Most Two Lines of Systemic Treatment in the Past

Start date: 2024-08-26
Primary completion: 2026-08-26
Enrollment: 252

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.